Clinical Trial Update: Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating gemcitabine/oxaliplatin plus imatinib (Glivec) in gemcitabine-refractory pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Glivec (imatinib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Advanced Pancreatic Cancer | Phase 1 | Status: COMPLETED